GBA mutations in Parkinson disease: earlier death but similar neuropathological features

• Published in: European journal of neurology Vol. 24; no. 11; pp. 1363 - 1368
• Main Authors: Adler, C. H., Beach, T. G., Shill, H. A., Caviness, J. N., Driver‐Dunckley, E., Sabbagh, M. N., Patel, A., Sue, L. I., Serrano, G., Jacobson, S. A., Davis, K., Belden, C. M., Dugger, B. N., Paciga, S. A., Winslow, A. R., Hirst, W. D., Hentz, J. G.
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01-11-2017
• Subjects: Age Factors; Aged; Aged, 80 and over; Aging; Amyloid; Autopsies; Brain - pathology; Cerebral amyloid angiopathy; Disease control; Female; genetics; glucocerebrosidase; Glucosylceramidase; Glucosylceramidase - genetics; Group size; Health risks; Humans; Longevity - genetics; Longitudinal Studies; Male; Movement disorders; Mutation; Neurodegenerative diseases; Neurofibrillary tangles; Neuropathology; Parkinson Disease - genetics; Parkinson Disease - pathology; Parkinson's disease; Point mutation; Rarefaction; Risk Factors; Senile plaques; Substantia alba; Parkinson's disease; genetics; glucocerebrosidase; neuropathology
• ISSN: 1351-5101; 1468-1331
• DOI: 10.1111/ene.13395

Background and purpose
Mutations in the glucocerebrosidase (GBA) gene are known to be a risk factor for Parkinson's disease (PD). Data on clinicopathological correlation are limited. The purpose of this study was to determine the clinicopathological findings that might distinguish PD cases with and without mutations in the GBA gene.
Methods
Data from the Arizona Study of Aging and Neurodegenerative Disorders were used to identify autopsied PD cases that did or did not have a GBA gene mutation. Clinical and neuropathological data were compared.
Results
Twelve PD cases had a GBA mutation and 102 did not. The GBA mutation cases died younger (76 vs. 81 years of age) but there was no difference in disease duration or clinical examination findings. No neuropathological differences were found in total or regional semi‐quantitative scores for Lewy‐type synucleinopathy, senile plaques, neurofibrillary tangles, white matter rarefaction or cerebral amyloid angiopathy scores.
Conclusions
In longitudinally assessed, autopsied PD cases, those with GBA mutations had a younger age at death but there was no evidence for clinical or neuropathological differences compared to cases without GBA mutations. Due to the small GBA group size, small differences cannot be excluded.